PR Newswire
WILMINGTON, Del., Feb. 11, 2026
The growth of the genomics market is driven by the rising prevalence of genetic disorders and cancer, along with increasing awareness of early disease detection through genetic testing.
WILMINGTON, Del., Feb. 11, 2026 /PRNewswire/ — Allied Market Research published a report, titled, «Genomics Market by Product (Consumables and Reagent, Services, Instruments and Systems and Software), Technology (Sequencing, PCR, Flow Cytometry, Microarray and Others), Application (Functional Genomics, Epigenomics, Pathway Analysis, Biomarker Discovery and Others), and End User (Clinical Research, Academic and Government Institutions, Hospitals and Clinics, Pharmaceutical and Biotechnology Companies and Others): Global Opportunity Analysis and Industry Forecast, 2024-2033″. According to the report, the genomics market was valued at $33.2 billion in 2023, and is estimated to reach $97.1 billion by 2033, growing at a CAGR of 11.5% from 2024 to 2033.
https://mma.prnewswire.com/media/636519/Allied_Market_Research_Logo.jpg
Key Factors Supporting Growth of the Genomics Market
Expanding applications in precision medicine and drug discovery further accelerate market adoption. However, high sequencing costs and concerns related to data privacy and reimbursement policies may restrain growth. Meanwhile, technological advancements and expanding healthcare and research infrastructure in emerging economies present significant opportunities for market expansion in the coming years.
Request Sample of the Report on Global Genomics Market 2033 –
https://www.alliedmarketresearch.com/request-sample/5474
The consumables and reagents segment generated the highest revenue in 2023
By product, the consumables and reagents segment accounted for the largest market share in 2023. Library preparation kits, sequencing reagents, and PCR consumables are essential for routine genomic workflows. Their recurring usage in laboratories, diagnostic centers, and pharmaceutical research drives consistent demand, supporting revenue growth compared to instruments, systems, software, and services.
The sequencing segment generated the highest revenue in 2023
By technology, the sequencing segment accounted for the highest revenue in the genomics market in 2023. Next-generation sequencing (NGS) is widely adopted due to its high accuracy, scalability, and declining cost per genome. It plays a critical role in oncology profiling, rare disease diagnosis, population genomics, and drug discovery. Continuous advancements in high-throughput platforms and bioinformatics tools further strengthened its market position across research and clinical applications.
The biomarker discovery segment generated significant revenue in 2023
By application, biomarker discovery held a substantial share of the genomics market in 2023. The growing focus on precision medicine and targeted therapies increased the need to identify reliable genetic biomarkers for disease diagnosis and treatment optimization. Functional genomics and epigenomics also contributed notably due to expanding molecular and gene expression research.
Want to Explore More, Connect to our Analyst –
https://www.alliedmarketresearch.com/connect-to-analyst/5474
The pharmaceutical and biotechnology companies segment generated the highest revenue in 2023
By end user, pharmaceutical and biotechnology companies accounted for the largest revenue share in 2023. These companies extensively utilize genomic technologies for drug discovery, target identification, and clinical trial optimization. Academic institutions, government organizations, hospitals, and clinics also contributed significantly to overall market demand.
Regional Outlook
Region wise, North America dominated the genomics market in 2023, supported by strong research funding, advanced healthcare infrastructure, and the presence of key industry players. For instance, in 2021 a significant investment in genomics research was made by the U.S. government, which announced a $1.7 billion funding initiative to enhance genomic sequencing capabilities across the U.S. The investment included an initial distribution of $240 million to states and other jurisdictions, the establishment of six Centers of Excellence in Genomic Epidemiology with a $400 million budget, and $300 million dedicated to developing a National Bioinformatics Infrastructure to support bioinformatics throughout the U.S. public health system. Europe held a significant share, while Asia-Pacific emerged as a rapidly growing region driven by increasing healthcare investments and expanding genomics research initiatives.
Key Players
- Color Genomics, Inc
- BGI Genomics
- Agilent Technologies
- Bio-Rad Laboratories, Inc
- Danaher Corporation
- Eppendorf AG
- Eurofins Scientific
- F. Hoffmann-La Roche Ltd.
- GE Healthcare
- Illumina, Inc.
The report provides a detailed analysis of these key players in the global genomics market. These players have adopted different strategies such as expansion, acquisition, product approval, product launch, and others to increase their market share and maintain dominant shares in different regions. The report is valuable in highlighting business performance, operating segments, product portfolio, and strategic moves of market players to showcase the competitive scenario. In May 2023, the U.S. Food and Drug Administration (FDA) granted approval to Illumina, Inc. for its next-generation sequencing (NGS)-based diagnostic platform designed to support comprehensive genomic profiling in oncology. The system enables high-throughput analysis with enhanced accuracy and faster turnaround times, strengthening the adoption of precision medicine in clinical settings.
Recent Industry Developments
In December 2022, BGI Genomics and the University of Pécs launched a joint laboratory to accelerate access to genetic testing applications. This facility will accelerate the development of genomic sequencing and clinical diagnostic services, while strengthening BGI Genomics and the UP’s leadership in genomics, bioinformatics, reproductive health, and precision medicine in the Central and Eastern European region.
In January 2024, Agilent announced the release of a new automated parallel capillary electrophoresis system for protein analysis, named The Agilent ProteoAnalyzer system. This new platform simplifies and improves the efficiency of analyzing complex protein mixtures, a process central to analytical workflows across the pharma, biotech, food analysis, and academia sectors.
For Purchase Related Queries/Inquiry –
https://www.alliedmarketresearch.com/purchase-enquiry/5474
How Has the Genomics Market Evolved in Recent Years?
The genomics market has experienced significant growth in recent years, driven by rapid advancements in sequencing technologies and increasing adoption of precision medicine. The declining cost of next-generation sequencing (NGS) and improvements in data analytics have made genomic testing more accessible across clinical and research settings. Hospitals, diagnostic laboratories, and research institutions now have enhanced access to high-throughput sequencing platforms and advanced bioinformatics tools, accelerating market adoption. In addition, growing awareness of early disease detection and personalized treatment planning has strengthened the clinical utility of genomics. Strategic collaborations among biotechnology companies, pharmaceutical firms, and academic institutions have further expanded research capabilities and accelerated innovation. Increased public and private investments in genomics research have also contributed to the expansion of testing services and infrastructure globally.
Get Customized Reports with your Requirements –
https://www.alliedmarketresearch.com/request-for-customization/5474
What Is the Growth Outlook for the Genomics Market?
The genomics market is expected to witness robust growth during the forecast period, supported by expanding applications in oncology, rare diseases, reproductive health, and drug discovery. Sequencing technology is anticipated to remain a key revenue contributor, while bioinformatics and data-driven solutions are projected to gain increasing importance. Rising healthcare investments, favorable regulatory developments, and integration of genomics into routine clinical workflows are creating strong growth opportunities. Asia-Pacific is expected to register the fastest growth due to expanding research initiatives and healthcare infrastructure, while North America and Europe are likely to maintain leading positions owing to established genomics ecosystems and strong funding support.
The report, published by Allied Market Research, focuses on market dynamics and key trends of genomics market analysis. The study provides competitive landscape analysis of the key players to understand the adopted strategies and competitive intensity of competitors. It also offers a study of threat of new entrants, and bargaining power of buyers, on the genomics market outlook.
Trending Reports in Healthcare Industry:
Oncology/Cancer Drugs Market – Global Opportunity Analysis and Industry Forecast, 2024-2033
U.S. Clinical Trial Imaging Services Market – Global Opportunity Analysis and Industry Forecast, 2024-2035
Digital Radiology/Radiography Market – Global Opportunity Analysis and Industry Forecast, 2024-2035
Hearing Care Devices Market – Global Opportunity Analysis and Industry Forecast, 2024-2030
Intravenous (IV) Therapy and Vein Access Market – Global Opportunity Analysis and Industry Forecast, 2024-2030
Surgical Scissors Market – Global Opportunity Analysis and Industry Forecast, 2024-2035
Cardiovascular Prosthetic Devices Market – Global Opportunity Analysis and Industry Forecast, 2024-2035
Rabies Vaccine Market – Global Opportunity Analysis and Industry Forecast, 2024-2035
AVENUE- A Subscription-Based Library (Premium on-demand, subscription-based pricing model) Offered by Allied Market Research:
AMR introduces its online premium subscription-based library Avenue, designed specifically to offer cost-effective, one-stop solution for enterprises, investors, and universities. With Avenue, subscribers can avail themselves of an entire repository of reports on more than 2,000 niche industries and more than 12,000 company profiles. Moreover, users can get online access to quantitative and qualitative data in PDF and Excel formats along with analyst support, customization, and updated versions of reports.
Get access to the library of reports at any time from any device and anywhere. For more details, follow the link: https://www.alliedmarketresearch.com/library-access
About Allied Market Research:
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Wilmington, Delaware. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of «Market Research Reports» and «Business Intelligence Solutions.» AMR has a targeted view to provide business insights and consulting to assist its clients in making strategic business decisions and achieve sustainable growth in their respective market domains. AMR offers its services across 11 industry verticals including Life Sciences, Consumer Goods, Materials & Chemicals, Construction & Manufacturing, Food & Beverages, Energy & Power, Semiconductor & Electronics, Automotive & Transportation, ICT & Media, Aerospace & Defense, and BFSI.
We are in professional corporate relations with various companies, and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality data and help clients in every way possible to achieve success. Each data presented in the reports published by us is extracted through primary interviews with top officials from leading companies in the domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.
Contact
David Correa
1209 Orange Street,
Corporation Trust Center,
Wilmington, New Castle,
Delaware 19801 USA.
Toll Free: +1-800-792-5285
Int’l: +1-503-894-6022
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1-855-550-5975
Web: https://www.alliedmarketresearch.com
Logo – https://mma.prnewswire.com/media/636519/Allied_Market_Research_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/genomics-market-to-reach-97-1-billion-by-2033-globally-at-11-5-cagr-allied-market-research-302685107.html
Tengo varias preguntas sobre esto a ver si me podiais aclarar:
-¿Puedo hacer un ingreso regular de 800 euros y me cobran 0euos de comisiones y mto.?
-¿Puedo sacar el dinero cuando quiera?,¿todo ó tengo entendido que hay que mantener un mínimo de 100 euros los 30 meses?
-No necesito pero me obligan a sacar una tarjeta de débito que me cuesta 11 euros el primer año y 22 euros la renovación, también otra de credito que me cuesta 0 euros el primer año y 35 euros la renovación.
¿Hay que mantenerlas 13 meses?
¿Puedo cancelar alguna de ellas desde el principio?
¿Puedo cancelar alguna de ellas antes de la renovación?
¿Hay alguna tarjeta de credito más barata?
Aparte de la cuenta nómina he visto que también que para que te den la tv también se puede sacar una cuenta tarifa plana básica o personal, ¿sabeis algo de estas cuentas?¿que requisitos tienen?
Muchas gracias a todos por responder
Yo fui a informarme y te cuento. Únicamente admiten los ingresos regulares en el caso de que seas autónomo. Te abren una cuenta Tarifa Plana Cero que está exenta de comisiones y presenta alguna ventaja más. Sobre dejar un mínimo de saldo en la cuenta no es necesario, pero sí te obligan a mantener varias tarjetas durante los 30 meses con un coste aproximado de 100 euros anuales.
hola buenas!
me llamo javi y estoy dudando de que banco, me puede dar mas beficios, sin sorpresas por domiciliar la nomina, ya que llevo años en la caixa y no me da nada ningun beneficio. es mas me rechazan los prestamos que solicito, ni siquiera una targeta de credito, por alegan de que siempre esta a cero la cuenta, yo cuando cobro la nomina dejo el dinero para los pagos, y saco el resto, pues no me fio, de que un dia me quede sin dinero, ya que esta todo muy mal, corre riesgo mi dinero o mis ahorros en el banco?? muchas gracias y un cordial saludo.
javi
NO TE EXTRAÑE QUE NO TE DEN LOS PTMOS, PORQUE LO QUE VEN ES QUE NO TIENES CAPACIDAD DE AHORRO PORQUE SIEMPRE DEJAS LA CTA. EN MINIMOS, ASI NINGUN BANCO TE LO VA A CONCEDER. TAMBIEN ES VERDAD QUE LA CAIXA, COMO TANTAS OTRAS CAJAS, TIENE EL PUÑO CERRADO PARA LOS RIESGOS, PARA REMONTAR. NO TE PREOCUPES, QUE POR UNA NOMINA NO CREO QUE NINGUN BANCO SE COJA LAS MANOS. LOS QUE SE TIENEN QUE PREOCUPAR SON LOS QUE TIENEN DÉPÓSITOS Y FONDOS EN BANCOS DE DUDOSA ACTIVIDAD. LA GENTE SE PIENSA QUE PORQUE LES DEN UN 7% YA ES UN GRAN BANCO Y SE EQUIVOCAN. LO QUE LES PASA ES QUE EL BANCO DE ESPAÑA LES PRESTA EL DINERO MAS CARO Y POR ESO OPTAN POR CONSEGUIRLO EN EL MERCADO MONETARIO, Y SI EL BANCO DE ESPAÑA NO SE FIA DE ELLOS, VA Y SE FIA LA GENTE. QUE LOS BANCOS NOES LA ADMON PUBLICA, ABRAN OS OJOS.
Hola , cuando vallais al banco queos dejen lo que hay que pagar de irpf y de iva sobre el valor de la tele ya que en la mayoria de bancos esto no lo dicen y luego llagan las sorpresas .A mi ya me ha pasado con la promoción del portatil y nunca me hablaros de esto . Cuidado
Yo he estado calculando y la tele entre unas cosas y otras te sale sobre unos 250euros que tampoco regalan tanto .Hay oficinas en las que han dado la occión de poner un dinero a plazo fijo a 12meses de 9300euros o 6800euros a 18 meses.
No es ningún chollo. Te obligan a contratar dos tarjetas de crédito que tienes que pagar porque las tienes que mantener 13 meses por lo menos y además llevan unos costes desproporcionados si las utilizas. En total, no usando las tarjetas y anulándolas una vez cumplidos los 13 meses puedes ahorrar unos 38 euros con respecto al precio de ese televisor en una gran superficie. Y además luego vendrá que te cobran para hacienda la retención correspondiente, por lo que probablemente incluso en las mejores condiciones te cueste más que si ahorras un poco y lña compras directamente.
Creó que teneis toda la razón, que aqui no te regalan nada, ya que a mí me paso con unas sartenes que regalaban el banco bilbao, que al final entre el irpf y el descuento de Hacienda, al final me salieron caras, así es que no os tomen el pelo, que al final siempre esta la letra pequeña que es la que nos joroba, por no decir otra cosa.
Yo saque el portatil y ahora me he sacado la TV LCD 32. Estas promos no hay que declararlas. No es obligado domiciliar nomina. Si, meter en la cuenta 800€ todos los meses en un margen de 10 dias. Cero matacero, pero cero,cero, cero de gastos de mantenimiento, ni por recibos, ni por el correo a casa, ni por transfer. Las tarjets gratis el 1er año. Resto fuera. Dadas de baja Menos la de debito. Banesto no pierde nada, ganar, gana clientes que es el proposito de esta promo. Precio de portatil y tv 32 en mercao unos 900€ los 2. En banest 197€. Los hay mejores, nos ha jodio! portatiles a 1200€, TV LCD 32 a 1000€. Señores, son lentejas. Relacion calida-precio-promo es cojonud…….Un saludit a los viandantes.
hola , no se si llegara mi comentario pero os voi a esplicar. esto es el cuento de la abuela. mira yo tengo el portatil. y he cogio tab la tele, pero sabeis ke?, me ha pasado de todo. os esplico. primero me cobran 74 euros y 25 euros de unas tarjetas que yo no las he visto aparecer por mi casa , me cabreo con el banco. llamo y pido esplicaciones. me dicen que van en la promocion, nunca jamas nadie me informo de las tarjetas, no me devuelven el dinero. me cabreo y me dicen que llame aun numero de tefono para darlas de baja, se pasan los dias, intentamos darlas de baja. largas y larga, que si este numero de tefono que si el otro bla bla bla. conseguimos hablar y nos dicen que tenemos que cambiar el contrato a tarifa plana o no se ke historias, llamando al banco se pasan los dias, largas y largas. me cabreo y estoi por suspender todo, me dicen que si lo quiero cambiar y dar de baja las tarjetas que nunca he tenido. tengo que pagar comisiones cada seis meses de doce y pico euros, y que si no quiero que me cobren comisiones tengo que ir todos los meses al banco a hacerlo yo, ufffffffffff.aun hay mas. me dan de baja y me hacen la tarifa plana, se equivocan un monton de veces. me hacen pasar muchos cabreos.y al final cuando llego a casa me han cobrado 25, 50 euros. y llamo por telefono y se lo digo , me dicen claro por dar de baja la otra cuenta , la madre que los pario. ladrones. o sea os digo que la tele no sale regalada, se la cobran y muy bien cobrada , nadie da nada por nada. en cuento termine de pagar lo que debo quito todas las cuentas del banesto.espero que alguien me lea y que me conteste gracias .
Banesto ha jodido a mi marido y a un amigo tambien. Para mi, despues de Banco de Andalucía son los peores. Y quieran creerlo o no ni la television ni el portátil te lo regalan.. como no cumplas cualquiera de las reglas te sancionan con 300 y pico de euros.. porque nos hemos mudado de casa y los recibos domiciados se cortaron «temporalmente» la sancion fue de mas de 300 euros.. y el cabreo q te llevas cuando ves lo q te han descontado y luego para ir a reclamarlos.. y como te tratan !! en fin.. espero que Banesto sea lo primero en undirse en el fin del mundo!!
CHOLLO!!!!!!!!!JAJAJAJAJA…….NO ES NINGUN CHOLLO!!!!!!! te cobran 100 € de gastos de manipulacion, mas 150 € en tarjetas durante 2 años, mas 6 € mensuales de mantenimiento de cuenta durante 30 meses, total que pagas 630 Euros por un ordenador o una TV que su valor seguro que no llega a 500 €. Y encima si vas a cancelar la cuenta cuando cumples los 30 meses requeridos te hacen esperar dos horas para decirte que no tienen linea de telefono para dar de baja la cuenta, cosa que no para nunca cuando vas a contratarlo. Y del trato que dispensan….., es el mismo que si vas con un fajo de billetes de 500 € por los CO-JONES
Banesto «premia», menuda falacia…
No hay ningún banco que premie a nadie.
BANESTO NECESITA NUESTRAS NÓMINAS, Y EN CUANTO VAS UN POCO JUSTO, COMO BUENOS JUDÍOS Y ÁVAROS QUE SON, TE ACOSAN Y MACHACAN, Y TE SACAN HASTA LAS ENTRAÑAS EN COMISIONES.
DESPUÉS EL ESTADO APOYA A LOS BANCOS, CON LA EXCUSA DE QUE SI CAEN LOS BANCOS CAEMOS TODOS. LOS BANCOS NECESITAN UN BOICOT DE VEZ EN CUANDO, PARA QUE NO NOS RESTREGUEN POR LA CARA SUS BENEFICIOS.
POR CIERTO, LO QUE MÁS FASTIDIA A UN BANCO ES UNA RECLAMACIÓN EN LA OFICINA DEL CONSUMIDOR Y OTRA AL BANCO DE ESPAÑA.
ES POR DAR PISTAS…